Status:
COMPLETED
Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Depressive Disorder
Depression
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.
Detailed Description
Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. This study will determine whether ethyl-EPA, an omega-3 fatty acid, can be used safely and effectively to treat major...
Eligibility Criteria
Inclusion
- Major depressive disorder
Exclusion
- Serious comorbid psychiatric disorder
- Unstable medical illness
- Prior use of any omega-3 fatty acid product
Key Trial Info
Start Date :
September 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00096798
Start Date
September 1 2001
End Date
August 1 2007
Last Update
January 17 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114